Finally, a recent study from our group demonstrated that high levels of phosphorylated Y88 p27 led to increased resistance to Palbociclib, in KRAS-mutated colorectal cancer, but administration of the Src-inhibitor Saracatinib was able to restore Palbociclib sensitivity, both in vitro and in vivo (57) (Figure 2). Here, KRAS is linked to colorectal cancer.